Global Blood Therapeutics (LSE:0IVZ) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

0IVZ Aktienübersicht

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).

Über das Unternehmen

0IVZ grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Trading at 66.8% below our estimate of its fair value

Earnings are forecast to grow 66.18% per year

Risikoanalyse

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Global Blood Therapeutics, Inc. Wettbewerber

Genus

LSE:GNS

UK£1.1b

Avacta Group

AIM:AVCT

UK£153.4m

PureTech Health

LSE:PRTC

UK£460.4m

NIOX Group

AIM:NIOX

UK£285.0m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Global Blood Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$68.48
52-Wochen-Hoch	US$72.00
52-Wochen-Tief	US$21.75
Beta	0.46
11 Monat Veränderung	0.94%
3 Monate Veränderung	126.38%
1 Jahr Veränderung	163.74%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	13.85%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	0IVZ	GB Biotechs	GB Markt
7D	0.9%	-2.4%	0.6%
1Y	163.7%	-25.6%	8.3%

Rendite im Vergleich zur Industrie: 0IVZ exceeded the UK Biotechs industry which returned -38.4% over the past year.

Rendite vs. Markt: 0IVZ exceeded the UK Market which returned -12.6% over the past year.

Preisvolatilität

Is 0IVZ's price volatile compared to industry and market?
0IVZ volatility
0IVZ Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.7%

Stabiler Aktienkurs: 0IVZ's share price has been volatile over the past 3 months.

Volatilität im Zeitverlauf: Insufficient data to determine 0IVZ's volatility change over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2011	457	Ted Love	www.gbt.com

Global Blood Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Global Blood Therapeutics im Vergleich zum Marktanteil des Unternehmens?
0IVZ grundlegende Statistiken
Marktanteil	US$4.62b
Gewinn(TTM)	-US$322.46m
Umsatz(TTM)	US$234.86m

19.7x

Kurs-Umsatz-Verhältnis

-14.3x

Kurs-Gewinn-Verhältnis

Ist 0IVZ zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
0IVZ Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$234.86m
Kosten der Einnahmen	US$4.45m
Bruttogewinn	US$230.41m
Sonstige Ausgaben	US$552.87m
Umsatz	-US$322.46m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-4.78
Bruttomarge	98.10%
Nettogewinnspanne	-137.30%
Schulden/Eigenkapital-Verhältnis	491.7%

Wie hat sich 0IVZ auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

0IVZ Aktienübersicht

Belohnungen

Risikoanalyse

Global Blood Therapeutics, Inc. Wettbewerber

LSE:GNS

UK£1.1b

AIM:AVCT

UK£153.4m

LSE:PRTC

UK£460.4m

AIM:NIOX

UK£285.0m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Recent updates

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Second quarter 2022 earnings released: US$1.26 loss per share (vs US$1.12 loss in 2Q 2021)

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

First quarter 2022 earnings released: US$1.26 loss per share (vs US$1.21 loss in 1Q 2021)

No longer forecast to breakeven

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Forecast to breakeven in 2024

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director

Revenue beats expectations

Global Blood Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Global Blood Therapeutics, Inc. Expands Access Protocol for Oxbryta in Pediatric Patients with Sickle Cell Disease

European Medicines Agency Accepts Global Blood Therapeutics, Inc.’s Marketing Authorization Application for Oxbryta (Voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Global Blood Therapeutics, Inc. Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

Global Blood Therapeutics, Inc. Initiates Early Access Program for Voxelotor

Revenue misses expectations

Global Blood Therapeutics, Inc. Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Global Blood Therapeutics, Inc.'s Grundlagenzusammenfassung

19.7x

-14.3x

Erträge &amp; Einnahmen

Erträge & Einnahmen